RxDoctor Payments Data

Christa Teasley

Family · Athens, GANPI 1700981958

Payments from drug & device makers

$466in general payments, 2019–2025

Across 26 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$163
  • AbbVie$65
  • Novartis$52
  • Teva Pharmaceuticals USA, Inc.$27
  • Elucent Medical$24
  • AstraZeneca$20
  • plus $115 from 8 others

What the payments were for

  • Food & beverage$466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$466 in reported general payments places this provider in the 50th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$234,111
Medicare patients
194
Services billed
2,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$61,740
Invega SustennaPaliperidone Palmitate11$39,514
MyrbetriqMirabegron52$21,789
JanuviaSitagliptin Phosphate38$20,634
TrulicityDulaglutide13$13,473
JardianceEmpagliflozin19$11,727
Tresiba Flextouch U-100Insulin Degludec15$8,117
NamzaricMemantine Hcl/Donepezil Hcl13$8,111
Cyclosporine20$7,497
GemtesaVibegron12$6,991
TradjentaLinagliptin12$6,801
XareltoRivaroxaban11$6,572
BrilintaTicagrelor12$5,614
LumiganBimatoprost17$4,364
Memantine Hcl145$3,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$16$46,08622 claims
AbbVieNamzaric, Lumigan, Synthroid$65$13,86557 claims
AstraZenecaBrilinta$20$5,61412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,258 family providers in Georgia.

Other family in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →